ULVR

4,108

-9.43%↓

DGE

1,390.5

-1.21%↓

ADM

3,134

-1.07%↓

ULVR

4,108

-9.43%↓

DGE

1,390.5

-1.21%↓

ADM

3,134

-1.07%↓

ULVR

4,108

-9.43%↓

DGE

1,390.5

-1.21%↓

ADM

3,134

-1.07%↓

ULVR

4,108

-9.43%↓

DGE

1,390.5

-1.21%↓

ADM

3,134

-1.07%↓

ULVR

4,108

-9.43%↓

DGE

1,390.5

-1.21%↓

ADM

3,134

-1.07%↓

Strona główna・Stock List・Tate & Lyle PLC

Tate & Lyle PLC

Open

SectorConsumer defensive

350 -2.51

Buy Sell

Overview

Share price change

24h

Current

Min

346.2

Max

367.2

Key metrics
By Trading Economics
Income	56M
Sales	1B
P/E Sector Avg	51.714 28.921
Dividend yield	5.57
Profit margin	5.469
Employees	5,000
EBITDA	188M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+10.47% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	5.57% 3.78%
Next Earnings	21 maj 2026

Market Stats
By TradingEconomics
Market Cap	1.6B
Previous open	352.51
Previous close	350

News Sentiment

By Acuity

24%

76%

19 / 131 Ranking in Consumer defensive

Tate & Lyle PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 mar 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Earnings

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 kwi 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Acquisitions, Mergers, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Earnings

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Market Talk

Earnings

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Earnings

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Earnings

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Earnings

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Earnings

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Earnings

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Earnings

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Market Talk

Earnings

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Earnings

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Earnings

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Earnings

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Earnings

Nike CEO: Converse Remains Important to Portfolio

Peer Comparison

Price change

Tate & Lyle PLC Forecast

Price Target

By TipRanks

10.47% upside

12 Months Forecast

Average 396.36 GBX 10.47%

High 500 GBX

Low 299.074 GBX

Based on 3 Wall Street analysts offering 12 month price targets forTate & Lyle PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Tate & Lyle PLC - Dist in the past 3 months.

Sentiment

By Acuity

19 / 131 Ranking in Consumer defensive

Financials

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Tate & Lyle PLC

Tate & Lyle plc, together with its subsidiaries, engages in the provision of ingredients and solutions to the food, beverage, and other industries in North America, Asia, Middle East, Africa, Latin America, and Europe. The company operates through three segments: Food & Beverage Solutions, Sucralose, Primary Products Europe, and Primient. It offers dairy products, soups, sauces, and dressings; bakery products and snacks; texturants; sweeteners, such as high fructose corn syrup and dextrose; industrial starches; acidulants; and corn gluten feed and meal and corn oil. The company was incorporated in 1903 and is headquartered in London, the United Kingdom.